{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T20:03:29Z","timestamp":1766088209608,"version":"build-2065373602"},"reference-count":113,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hoc.2023.12.003","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T05:14:59Z","timestamp":1704777299000},"page":"361-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bispecific Antibodies in the Treatment of Multiple Myeloma"],"prefix":"10.1016","volume":"38","author":[{"given":"Xiang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianghui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus Martin","family":"Kortuem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.hoc.2023.12.003_bib1","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.hoc.2023.12.003_bib2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.003_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"year":"2020","series-title":"The epidemiology, management and impact of surgical wounds healing by secondary intention: a research programme including the SWHSI feasibility RCT","author":"Chetter","key":"10.1016\/j.hoc.2023.12.003_bib4"},{"issue":"10068","key":"10.1016\/j.hoc.2023.12.003_bib5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.003_bib6","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.003_bib7","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3390\/jcm9072166","article-title":"Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma","volume":"9","author":"Zhou","year":"2020","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.003_bib8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1535-6108(03)00113-2","article-title":"Adoptive immunotherapy: engineering T\u00a0cell responses as biologic weapons for tumor mass destruction","volume":"3","author":"Ho","year":"2003","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.003_bib9","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.7150\/ijms.46811","article-title":"Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis","volume":"18","author":"Yang","year":"2021","journal-title":"Int J Med Sci"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.003_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/hematology.2022000334","article-title":"Antibodies and bispecifics for multiple myeloma: effective effector therapy","volume":"2022","author":"Cipkar","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.003_bib11","first-page":"332","article-title":"FDA approves first BCMA-targeted CAR-T cell therapy","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.003_bib12","first-page":"249","article-title":"FDA approves second BCMA-targeted CAR-T cell therapy","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"16","key":"10.1016\/j.hoc.2023.12.003_bib13","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","article-title":"Teclistamab: First Approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.hoc.2023.12.003_bib14","first-page":"119","article-title":"CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges","volume":"12","author":"Rendo","year":"2022","journal-title":"Blood Lymphat Cancer"},{"issue":"13","key":"10.1016\/j.hoc.2023.12.003_bib15","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1080\/10428194.2022.2113532","article-title":"T\u00a0cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape","volume":"63","author":"Kazandjian","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.003_bib16","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/10781552231154809","article-title":"Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed\/refractory multiple myeloma","volume":"29","author":"Granger","year":"2023","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.003_bib17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/(SICI)1097-0215(19980717)77:2<251::AID-IJC14>3.0.CO;2-E","article-title":"Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms","volume":"77","author":"Link","year":"1998","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.003_bib18","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.003_bib19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5\/CD3 and Is a Requirement for Myeloma Cell Killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.003_bib20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.hoc.2023.12.003_bib21","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1182\/bloodadvances.2020002565","article-title":"AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys","volume":"4","author":"Goldstein","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.003_bib22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"mAbs"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.003_bib23","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.clml.2019.08.002","article-title":"SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents","volume":"19","author":"Madduri","year":"2019","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.003_bib24","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov Today"},{"issue":"26","key":"10.1016\/j.hoc.2023.12.003_bib25","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.2021014611","article-title":"T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?","volume":"139","author":"Moreau","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.003_bib26","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3324\/haematol.2020.266841","article-title":"BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice","volume":"108","author":"Zhou","year":"2023","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.hoc.2023.12.003_bib27","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.003_bib28","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2023.12.003_bib29","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","article-title":"Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment","volume":"66","author":"Tai","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.003_bib30","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.hoc.2023.12.003_bib31","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/blood-2009-09-243535","article-title":"Classical and\/or alternative NF-kappaB pathway activation in multiple myeloma","volume":"115","author":"Demchenko","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2023.12.003_bib32","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T\u00a0cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.003_bib33","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A\u00a0novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in\u00a0vitro and in\u00a0vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.003_bib34","doi-asserted-by":"crossref","first-page":"e0151118","DOI":"10.1371\/journal.pone.0151118","article-title":"Comparative Transcriptome Analysis of Fetal Skin Reveals Key Genes Related to Hair Follicle Morphogenesis in Cashmere Goats","volume":"11","author":"Gao","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.003_bib35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG family member, GPRC5D, is associated with hard-keratinized structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J\u00a0Invest Dermatol"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.003_bib36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.5021\/ad.2017.29.5.597","article-title":"Comprehensive Transcriptome Profiling of Balding and Non-Balding Scalps in Trichorhinophalangeal Syndrome Type I Patient","volume":"29","author":"Kim","year":"2017","journal-title":"Ann Dermatol"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.003_bib37","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.003_bib38","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1179\/1607845413Y.0000000079","article-title":"GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells","volume":"18","author":"Cohen","year":"2013","journal-title":"Hematology"},{"issue":"485","key":"10.1016\/j.hoc.2023.12.003_bib39","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"15","key":"10.1016\/j.hoc.2023.12.003_bib40","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A\u00a0T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.003_bib41","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol Cancer Therapeut"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.003_bib42","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","article-title":"Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia","volume":"18","author":"Polson","year":"2006","journal-title":"Int Immunol"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.003_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-019-0178-8","article-title":"Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma","volume":"9","author":"Stewart","year":"2019","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.003_bib44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0002-9440(10)63276-2","article-title":"Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma","volume":"165","author":"Inoue","year":"2004","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.003_bib45","first-page":"54","article-title":"Human CD38, a surface receptor, an enzyme, an adhesion molecule and not a simple marker","volume":"13","author":"Funaro","year":"1999","journal-title":"J\u00a0Biol Regul Homeost Agents"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.003_bib46","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma","volume":"121","author":"Lin","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.003_bib47","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.hoc.2023.12.003_bib48","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.hoc.2023.12.003_bib49","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38\/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release","volume":"25","author":"Zuch de Zafra","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.003_bib50","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41375-019-0519-4","article-title":"Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination","volume":"34","author":"Akhmetzyanova","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.003_bib51","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1096\/fj.02-0739rev","article-title":"Syndecans in inflammation","volume":"17","author":"Gotte","year":"2003","journal-title":"Faseb J"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.003_bib52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/08923973.2016.1153110","article-title":"Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization","volume":"38","author":"Chen","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.hoc.2023.12.003_bib53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fimmu.2014.00137","article-title":"Immunophenotype of normal and myelomatous plasma-cell subsets","volume":"5","author":"Robillard","year":"2014","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.003_bib54","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.leukres.2013.12.007","article-title":"Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases","volume":"38","author":"Tembhare","year":"2014","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.003_bib55","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1038\/s41467-019-10948-w","article-title":"Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T","volume":"10","author":"Nerreter","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.003_bib56","doi-asserted-by":"crossref","first-page":"e709","DOI":"10.1634\/theoncologist.2019-0559","article-title":"Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease","volume":"25","author":"Ali","year":"2020","journal-title":"Oncol"},{"issue":"5891","key":"10.1016\/j.hoc.2023.12.003_bib57","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T\u00a0cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.003_bib58","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.003_bib59","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.003_bib60","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.hoc.2023.12.003_bib61","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1182\/blood-2008-10-183772","article-title":"CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells","volume":"113","author":"Tai","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.003_bib62","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.003_bib63","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-016-0284-z","article-title":"Elotuzumab for the treatment of multiple myeloma","volume":"9","author":"Wang","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.003_bib64","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/2040620716652862","article-title":"Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment","volume":"7","author":"Magen","year":"2016","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.003_bib65","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nbt0216-126","article-title":"FDA approves three different multiple myeloma drugs in one month","volume":"34","author":"Ratner","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.003_bib66","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/2326-6066.CIR-17-0649","article-title":"A\u00a0CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.003_bib67","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib68","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-134063","article-title":"A\u00a0Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE\u00ae (bispecific T-cell engager) Molecule, in Relapsed\/Refractory (RR) Multiple Myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.003_bib69","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib70","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2022-159711","article-title":"Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study","volume":"140","author":"Searle","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2023.12.003_bib71","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/JCO.2022.40.16_suppl.8032","article-title":"A\u00a0novel, immunotherapy-based approach for the treatment of relapsed\/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody)","volume":"40","author":"Rodr\u00edguez-Otero","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.003_bib72","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib73","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2021-148723","article-title":"Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed\/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study","volume":"138","author":"Rodriguez-Otero","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib74","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1182\/blood-2022-159756","article-title":"MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab\u00a0+ Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma","volume":"140","author":"Zamagni","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib75","doi-asserted-by":"crossref","first-page":"10148","DOI":"10.1182\/blood-2022-160173","volume":"140","author":"Krishnan","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib76","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2021-150519","article-title":"Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1","volume":"138","author":"Sebag","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib77","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1182\/blood-2021-152984","article-title":"Magnetismm-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma","volume":"138","author":"Lesokhin","year":"2021","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2023.12.003_bib78","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/JCO.2023.41.16_suppl.8039","article-title":"Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study","volume":"41","author":"Tomasson","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2023.12.003_bib79","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2019-122895","article-title":"First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1\u00a0T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib80","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood-2022-159009","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study","volume":"140","author":"Wong","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2023.12.003_bib81","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2023.41.16_suppl.8006","article-title":"LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Bumma","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"10.1016\/j.hoc.2023.12.003_bib82","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A\u00a0Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen x CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"40","author":"D'Souza","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.003_bib83","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.hoc.2023.12.003_bib84","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib85","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood-2021-146868","article-title":"Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"138","author":"Krishnan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.003_bib86","doi-asserted-by":"crossref","unstructured":"Cohn Y, Morillo D. First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM), J Clin Oncol, 41, (16_suppl), 2023, 8002.","DOI":"10.1200\/JCO.2023.41.16_suppl.8002"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2023.12.003_bib87","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec)\u00a0+ talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Morillo","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.003_bib88","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.HS9.0000843612.41180.42","article-title":"S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED\/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL","volume":"6","author":"Hasselbalch Riley","year":"2022","journal-title":"HemaSphere"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.003_bib89","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","article-title":"Infectious complications of bispecific antibody therapy in patients with multiple myeloma","volume":"13","author":"Sim","year":"2023","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.hoc.2023.12.003_bib90","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib91","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136985","article-title":"Initial Clinical Activity and Safety of BFCR4350A, a FcRH5\/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Cohen","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib92","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib93","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed\/Refractory Multiple Myeloma: Early Experience from a Phase I Study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib94","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1182\/blood-2022-157525","article-title":"Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"140","author":"Mohan","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.003_bib95","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ctrv.2018.04.002","article-title":"Bispecific antibodies in haematological malignancies","volume":"65","author":"Viardot","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.003_bib96","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1097\/HS9.0000000000000575","article-title":"Understanding the Mechanisms of Resistance to T Cell-based Immunotherapies to Develop More Favorable Strategies in Multiple Myeloma","volume":"5","author":"Ahn","year":"2021","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.003_bib97","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T\u00a0cells in a patient with multiple myeloma","volume":"27","author":"Da Via","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.003_bib98","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T\u00a0cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2023.12.003_bib99","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/blood-2019-122451","article-title":"Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed\/Refractory (R\/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)","volume":"134","author":"Bannerji","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib100","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood-2018-99-113328","article-title":"Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes","volume":"132","author":"Bannerji","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib101","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-141187","article-title":"Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma","volume":"136","author":"Verkleij","year":"2020","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2023.12.003_bib102","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T\u00a0cell-engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib103","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood-2022-167602","article-title":"Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)","volume":"140","author":"Lee","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.003_bib104","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-137650","article-title":"Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy","volume":"136","author":"Leblay","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.003_bib106","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2023.12.003_bib107","doi-asserted-by":"crossref","first-page":"8034","DOI":"10.1200\/JCO.2023.41.16_suppl.8034","article-title":"Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study","volume":"41","author":"Karlin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.003_bib108","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2022-164717","article-title":"Dysfunctional Hyper-Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma","volume":"140","author":"Neri","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.003_bib109","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T\u00a0cell landscape determines the response to bispecific T\u00a0cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.hoc.2023.12.003_bib110","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.003_bib111","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T\u00a0cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"12_Supplement","key":"10.1016\/j.hoc.2023.12.003_bib112","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/1538-7445.AM2022-5588","article-title":"Abstract 5588: PD-1 blockade synergizes with IMiDs to enhance bispecific T\u00a0cell engager immune responses to Vk\u2217MYChCRBN multiple myeloma by preventing T\u00a0cell exhaustion","volume":"82","author":"Meermeier","year":"2022","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2023.12.003_bib113","first-page":"S13","article-title":"Bispecific T-cell engagers for treatment of multiple myeloma","volume":"98","author":"Ravi","year":"2023","journal-title":"Am J Hematol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:19:29Z","timestamp":1760591969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823001703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":113,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0889858823001703"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific Antibodies in the Treatment of Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}